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Abstract
Background: The purposes of this study are to evaluate the prognostic value of posttreatment 18F-FDG PET/CT in
predicting the survival of patients with ovarian carcinoma and to determine incremental value of combining
posttreatment PET/CT with traditional prognostic factors in a multivariate model.
Methods: This was an IRB-approved retrospective study. From July 2001 to July 2011, 48 patients who completed
initial therapy for ovarian carcinoma with concurrent 3- to 9-month initial posttreatment 18F-FDG PET/CT and serum
CA-125 were identified from the radiology database. Prognostic value of posttreatment PET/CT, CA-125, age, race,
and tumor stage were determined from Cox proportional hazard model using univariate and multivariate analyses.
Time-dependent receiver operator curves were also calculated at various follow-up intervals.
Results: In a univariate model, overall survival (OS) was associated with PET/CT (hazard ratio = 4.18; 95 % CI
1.49–11.70) and CA-125 (hazard ratio = 11.09; 95 % CI 4.27–28.79). When the effects of posttreatment PET/CT and
CA-125 were combined in the multivariate analysis, hazard ratio for PET/CT increased to 4.84 (95 % CI 1.59–14.73,
p = 0.005) and hazard ratio for CA-125 increased to 14.43 (95 % CI 4.65–44.84, p < 0.001). In the subset of patients
with negative CA-125, posttreatment PET/CT had a hazard ratio of 2.98 (95 % CI 0.86–10.37), supporting the role
of posttreatment PET/CT in risk stratification of patients with negative CA-125. Time-dependent receiver operator
curves showed that the combination of PET/CT and CA-125 improved prognostic accuracy compared to PET/CT
or CA-125 alone at 12-, 24-, 30-, and 36-month follow-up.
Conclusions: Posttreatment PET/CT can predict the survival of patients with ovarian carcinoma. The addition of
posttreatment PET/CT to the CA-125 serum biomarker has an incremental value in improving prognostic
accuracy, particularly in the subset of patients with negative CA-125.
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Background
Ovarian cancer is diagnosed in 65,500 women each year
in Europe and results in 42,700 deaths yearly [1]. Al-
though responsible for <30 % of all gynecologic malig-
nancies, ovarian cancer accounts for >50 % of deaths
[2]. Most patients are diagnosed at advanced stage [3],
and 5-year survival for ovarian cancer has been reported
to be between 35 and 44 % [3, 4]. Primary cytoreductive
surgery followed by taxane and platinum-based combin-
ation chemotherapy is the mainstay of treatment for
women with advanced stage ovarian cancer [5, 6]. Despite
achievement of complete clinical response, recurrence
rates remain high. 18F-fluorodeoxyglucose positron emis-
sion tomography/computed tomography (18F-FDG PET/
CT) has been shown to detect active disease at relatively
low levels of CA-125, thereby facilitating early diagnosis of
recurrence or residual disease [7]. The reported sensitivity
and specificity of PET alone and PET/CT in the detection
of recurrent ovarian cancer range from 45.3 to 92.3 % and
73.0 to 100 % [8–12]. PET/CT has been shown to alter
clinical management in patients with suspected recur-
rent ovarian cancer in 60 % of cases [13]. Pretreatment
PET/CT has been shown to predict disease recurrence
and overall survival in patients with ovarian cancer
[14–16]. Evangelista et al. and Liao et al. have shown
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that posttreatment PET/CT obtained between 1 and
109 months after the treatment for ovarian cancer was
helpful in predicting patient survival [17, 18]. However,
Kurosaki et al. showed that posttreatment PET/CT was
not significant in predicting patient survival [19].
Currently, the prognostic impact of surveillance post-
treatment PET/CT and the ideal time window for sur-
veillance imaging have not been firmly established. In
fact, current guidelines by the National Comprehensive
Cancer Network (NCCN) and the Society of Gyneco-
logic Oncologists state that there is insufficient evi-
dence to support the use of PET/CT in routine
surveillance [2, 6]. The purposes of this study are to
evaluate the prognostic impact of surveillance post-
treatment PET/CT in predicting survival of ovarian
cancer patients and to compare the prognostic value of
PET/CT with CA-125 in predicting patient survival.
The potential prognostic impact of posttreatment PET/




This is an Institutional Review Board-approved retro-
spective study. From July 2001 to July 2011, 48 patients
(mean age of diagnosis 58.1 years) who completed initial
therapy for ovarian carcinoma with no known cancer re-
currence who underwent concurrent PET/CT and serum
CA-125 within 3 to 9 months of completion of primary
therapy for ovarian carcinoma were identified from the
radiology database (Table 1). Complete response to ini-
tial therapy was assessed based on normalization of
CA-125 levels and the absence of suspicious findings
on posttreatment CT within 1–2 months after comple-
tion of treatment. At our institution, patients usually
returned for clinical follow-up after initial treatment
every 2 to 4 months for the first 2 years. Complete his-
tory, physical exam, and CA-125 were obtained at each
clinical visit. CT and PET/CT were obtained as clinic-
ally appropriate for restaging in asymptomatic patients
and to evaluate for suspected recurrence based on clin-
ical findings and/or abnormal CA-125. The time win-
dow of 3 to 9 months was chosen as many ovarian
carcinoma patients presented for follow-up PET/CT
around 6 months posttreatment. 3 to 9 months gave a
3-month buffer window centered on the 6-month
follow-up scan. Three of the 48 patients underwent
more than one PET/CT exam during the 3- to 9-month
time window, and the latest PET/CT was used for the
analysis.
PET/CT scan technique
Patients fasted for a minimum of 4 h and had blood
glucose levels less than or equal to 200 mg/dL just
before the intravenous injection of 18F-FDG (8.14 MBq/
kg [0.22 mCi/kg]). Oral contrast was administered for
the CT portion of the study. After an uptake phase of
18F-FDG of approximately 60 min, a combined whole
body PET/CT scan (Discovery LS; GE Healthcare) was
performed. Single whole body CT was performed with
a four-slice multidetector helical scanner with oral con-
trast (no IV contrast) for attenuation correction pur-
pose. A CT transmission map was generated for image
fusion. Emission data were acquired for 5 min at each
bed position. PET images were reconstructed using the
ordered-subset expectation maximization algorithm (2
iterations, 28 subsets), an 8-mm Gaussian filter with a
128 × 128 matrix, and non-contrast-enhanced CT at-
tenuation correction.
Table 1 Patient demographics and clinical characteristics (n = 48)
Characteristic N (range or %)
Median (range) of age at diagnosis (years) 58.0 (35–85)
Median (range) between completion of initial
treatment and PET/CT (months)
6 (3–9)
Mean ± SD between completion of initial treatment
and PET/CT (months)
5.5 ± 1.9
Median follow-up timea (months) 47.3 (4.56–119.8)
Death events 22 (45.8 %)
Median baseline CA-125 (U/mL) 459 (14–8409)
Median CA-125 at follow-up (U/mL) 23.5 (2–626)
FIGO stage
I and II 4 (8.33 %)
III and IV 43 (89.58 %)
Unknown 1 (2.08 %)
Histologic type
Serous 35 (72.92 %)
Not serous 12 (25.00 %)
Unknown 1 (2.08 %)
Tumor grade
High 40 (83.33 %)
Low 2 (4.17 %)
Unknown 6 (12.50 %)
Residual disease
Optimal debulking 32 (66.67 %)
Suboptimal debulking 3 (6.25 %)
Unknown 13 (27.08 %)
Initial treatment
Surgery 48 (100 %)
Adjuvant chemotherapy 42 (87.5 %)
Radiation therapy 0 (0 %)
aMedian follow-up was calculated via reverse Kaplan-Meier method
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PET/CT and CA-125 data
PET/CT reports were systematically reviewed to deter-
mine the presence or absence of suspected disease re-
currence on PET/CT. PET/CT exams were interpreted
by junior and senior board-certified nuclear medicine
physicians ranging from 2 years to greater than 10 years
of experience. Reports that stated “findings compatible
with disease recurrence” or “findings suspicious for dis-
ease recurrence” were classified as presence of suspected
disease recurrence. Reports that stated “no evidence of
disease recurrence” or “findings most likely representing
posttreatment changes, with disease recurrence not en-
tirely excluded” were classified as absence of suspected
disease recurrence.
Medical records were reviewed to determine concur-
rent serum CA-125 within 1 month of PET/CT. Recur-
rence based on serum CA-125 was determined based
on the Gynecological Cancer InterGroup (GCIG) cri-
teria: In patients with elevated CA-125 pretreatment
and normalization of CA-125, recurrence was deter-
mined by CA-125 greater than, or equal to, two times
the upper limit of the reference range on two occasions
at least 1 week apart. In patients with elevated CA-125
before treatment, which never normalized, recurrence
was determined by CA-125 greater than, or equal to,
two times the nadir value on two occasions at least
1 week apart [20].
The sensitivity and specificity in detection of disease re-
currence with initial posttreatment PET/CT and CA-125
were compared to reference standard 6 months later.
Reference standard included pathologic confirmation,
elevated CA-125, and/or stable of increase in size of FDG
avid lesion on follow-up PET/CT.
Survival data
Patient mortality data was determined from the medical
record and social security death index. Overall survival
was defined from the completion of initial treatment to
death or censored at last follow-up date, up until 31
December 2014.
Statistical analysis
Kaplan-Meier curve was plotted by PET/CT results, by
CA-125 results, and by combination of PET/CT and
CA-125 results. Cox proportional hazard model was
used to evaluate the association of the prognostic factors
with survival. Univariate analysis of overall survival was
performed to examine the effects of PET scan, CA-125,
age, race, and initial tumor stage. These factors were
then carried on to a multivariate analysis. The ability of
the prognostic factor to distinguish between patients dif-
fering in survival was assessed using the C-statistic. The
C-statistic represents the probability that for a randomly
selected pair of patients, the one having higher predicted
survival is the one who survives longer. In addition, area
under the curve (AUC) from time-dependent receiver
operator curve (ROC) via nearest neighbor estimation
[21] for predicting survival at the time of interests (1, 2,
2.5, and 3 years) was considered as well. The larger value
of C-statistic and AUC indicates a better discrimination
ability of the prognostic performance. Statistical software
R 3.2.0 was performed through the analyses, and statis-
tical packages “Hmisc” and “survivalROC” were applied
for evaluating C-statistic and time-dependent ROC.
Results
Patient demographics and clinical characteristics are
summarized in Table 1. Median time between the com-
pletion of initial treatment and PET/CT was 6 months
(range 3 to 9 months; mean 5.5 ± 1.9 months). Twenty
four patients were asymptomatic with no clinical signs
of recurrence at time of exam. Twenty four patients had
suspected recurrence based on clinical exam, CT find-
ings, or elevated CA-125. Posttreatment PET/CT reports
showed findings “compatible with” or “suspicious for”
recurrence in 62.5 % (30/48) cases. Representative posi-
tive and negative PET/CT exams were shown in Figs. 1
and 2. Concurrent CA-125 was suspicious for recurrence
in 27.1 % (13/48) cases.
Both PET/CT and CA-125 were suspicious for recur-
rence in 25.0 % (12/48) cases. Both PET/CT and CA-125
were negative for recurrence in 35.4 % (17/58) cases.
PET/CT and CA-125 were discordant for recurrence in
39.6 % (19/48) cases, in which PET/CT was positive and
CA-125 was negative in 37.5 % (18/48) cases and PET/
CT was negative and CA-125 was positive in 2.1 % (1/
48) cases. In the 18 cases where PET/CT was positive
and CA-125 was negative, baseline CA-125 was elevated
in 61.1 % (11/18) cases, baseline CA-125 was within nor-
mal limits in 11.1 % (2/18) cases, and baseline CA-125
was unknown in 27.8 % (5/18) cases.
Forty one out of 48 (85.4 %) patients received add-
itional surgical resection and/or adjuvant chemotherapy
treatment following initial posttreatment PET/CT. The
sensitivity and specificity in detection of disease recur-
rence with initial posttreatment PET/CT and CA-125
were compared to reference standard 6 months later.
Reference standard showed evidence of disease recur-
rence in 79.2 % (38/48) of patients 6 months after the
initial posttreatment follow-up. It was based on patho-
logic confirmation in 45.8 % (22/48) cases. It was based
on clinical assessment in 54.2 % (26/48) cases, which
was defined as positive in the setting of persistently ele-
vated CA-125, and/or stable or increase in lesion size of
follow-up CT or PET/CT. PET/CT showed sensitivity of
78.9 % (30/38, 95 % CI 62.7–90.4 %), specificity of 100 %
(10/10, 95 % CI 58.7–100.0 %), and accuracy of 83.3 %
(40/48, 95 % CI 69.8–92.5 %). CA-125 showed sensitivity
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of 34.2 % (13/38, 95 % CI 19.6–51.4 %), specificity of
100 % (10/10, 95 % CI 58.7–100.0 %), and accuracy of
47.9 % (23/48, 95 % CI 33.3–62.8 %).
In the univariate analysis, PET/CT and serum CA-125
were statistically significant in the prediction of overall
survival (Table 2). The hazard ratio and C-statistic for
PET/CT were 4.18 (95 %CI 1.49–11.70) and 0.683, re-
spectively (p = 0.006). The hazard ratio and C-statistic for
CA-125 were 11.09 (95 % CI 4.27–28.79) and 0.744, re-
spectively (p < 0.001). The Kaplan-Meier overall survival
curves showed improved patient survival in patients with
negative posttreatment PET/CT (Fig. 3) or negative post-
treatment CA-125 (Fig. 4).
Multivariate analysis was performed including both
PET/CT and CA-125 to determine if the addition of
PET/CT to CA-125 would improve prognostic accur-
acy. In the multivariate analysis model including both
PET/CT and CA-125, the hazard ratio for PET/CT in-
creased to 4.84 (95 % CI 1.59–14.73) (p = 0.005) and
the hazard ratio for CA-125 increased to 14.43 (95 %
CI 4.65–44.84) (p < 0.001). C-statistic increased to
0.804 (Table 2).
Fig. 1 PET/CT of a 52-year-old ovarian cancer patient status post debulking and chemotherapy with active residual disease. Concurrent CA-125
was 89. a PET maximum intensity projection (MIP) image shows intensely FDG avid disease in the left supraclavicular lymph nodes, mediastinal
lymph nodes, retroperitoneal lymph nodes, and peritoneal implants. b Axial fused PET/CT image shows cluster of FDG avid retroperitoneal lymph
nodes. Volume of interest shows SUVmax of 8.67
Fig. 2 PET/CT of a 54-year-old ovarian cancer patient status post debulking and chemotherapy with no evidence of active residual disease.
Concurrent CA-125 was 5. a PET MIP image shows physiologic FDG uptake without evidence of active residual disease. b Axial-fused PET/CT
image shows physiologic intestinal FDG uptake in the right lower quadrant and the pelvis.
Chu et al. EJNMMI Research  (2016) 6:42 Page 4 of 8
For exploratory manner, in the subset of 35 patients
with negative CA-125, univariate analysis with posttreat-
ment PET/CT had a hazard ratio of 2.98 (95 % CI 0.86–
10.37) and C-statistic of 0.641, with p value of 0.086, sup-
porting the role of posttreatment PET/CT in risk stratifi-
cation of patients with negative CA-125. Kaplan-Meier
overall survival curve combining both posttreatment PET/
CT and CA-125 (Fig. 5) showed that patients with positive
PET/CT and positive CA-125 had the lowest likelihood of
overall survival and patients with negative PET/CT and
negative CA-125 had the highest likelihood of overall
survival. Patients with either positive PET/CT and nega-
tive CA-125 or negative PET/CT and positive CA-125 had
intermediate likelihood of overall survival. Posttreatment
PET/CT may play a role in risk stratification in patients
with negative CA-125, although a larger cohort will be
needed for further validation.
The time-dependent receiver operator curve analysis
also showed that adding PET/CT to CA-125 increased
the area under the ROC compared to PET/CT alone or
CA-125 alone at each of the 12-, 24-, 30-, and 36-
month follow-up time points (Fig. 6). For example, at
Table 2 Univariate overall survival analysis with age at
diagnosis, race, and initial tumor stage, PET/CT, and serum










Age 1.03 0.98 1.07 0.277 0.509
Race (White vs. non-
White)
0.53 0.16 1.82 0.316 0.518
Stage (stage ≥III vs.
stage <III)
1.02 0.24 4.41 0.975 0.513
Baseline CA-125
(log transformation)
0.90 0.48 1.68 0.73 0.58
PET/CT (+ vs. −) 4.18 1.49 11.70 0.006 0.683
CA-125 (+ vs. −) 11.09 4.27 28.79 <0.001 0.744
Multivariate analysis
PET/CT (+ vs. −) 4.84 1.59 14.73 0.005 0.804
CA-125 (+ vs. −) 14.43 4.65 44.84 <0.001
aDenotes confidence interval
Fig. 3 Kaplan-Meier overall survival curve by 18F-FDG PET/CT
Fig. 5 Kaplan-Meier overall survival curve by combination of 18F-FDG
PET/CT and concurrent CA-125; N negative, P positive
Fig. 4 Kaplan-Meier overall survival curve by CA-125
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the 12-month follow-up, area under the receiver oper-
ator curve was 0.90 for combination of PET/CT and
CA-125, compared with 0.70 for PET/CT alone and
0.89 for CA-125 alone. Receiver operator curves at 24-,
30-, and 36-month follow-up showed similar results,
with more increments compared to CA-125 alone.
Discussion
Posttreatment PET/CT has been shown to be sensitive
and specific in the detection of recurrent ovarian cancer
[8–12], and it has significant impact in altering clinical
management in patients with suspected recurrent ovar-
ian cancer [13]. Our results showed that initial posttreat-
ment PET/CT within 3 to 9 months was more sensitive
than CA-125 in detection of disease recurrence. PET/
CT detected disease recurrence in 62.5 % of ovarian can-
cer patients within 9 months of completing initial ther-
apy. This percentage may be higher than expected for
several reasons. PET/CTs were not routinely obtained in
all ovarian cancer patients within the first 9 months of
posttreatment at our institution. Our clinicians selected
a subset of patients to undergo surveillance PET/CT
based on clinical findings or CA-125 levels that place
patients at increased risk of disease recurrence. As a re-
sult, 50 % of our patients have suspected ovarian cancer
recurrence at the time of restaging PET/CT. In addition,
6.25 % of patients were known to have suboptimal
debulking at the time of surgery and 27.1 % of patients
had surgeries performed at outside institutions and it
was unknown in how many cases optimal debulking was
achieved.
Similar to previously published reports, patients with
either positive posttreatment PET/CT or positive CA-
125 had worse prognosis compared with patients with
negative posttreatment PET/CT and negative CA-125
[17, 18, 22]. Initial posttreatment CA-125 was more
predictive of overall survival than PET/CT, and this
trend was consistent across all of our statistical ana-
lyses, including Cox proportional hazard model, C-
statistic, Kaplan-Meier, and time-dependent receiver
operator curves. The addition of posttreatment PET/
CT to serum CA-125 may be valuable in risk stratifica-
tion of the subset of patients with negative CA-125,
which may be further validated in a larger cohort. Pre-
vious reports investigating effects of posttreatment
PET/CT and patient prognosis used studies ranging
from 1 to 109 months posttreatment [17, 19]. At our
institution, patients usually would have undergone mul-
tiple posttreatment PET/CTs during that time period,
and they may have both positive and negative PET/CTs
rendering the results difficult to interpret. We chose to
focus our population on the initial posttreatment PET/
CT within 3 to 9 months as patients often returned for
follow-up PET/CT at this time interval. Focusing on
Fig. 6 Time-dependent receiver operator curves on predicting survival with PET/CT, CA-125, and combination of PET/CT and CA-125, at a 12, b 24, c 30,
and d 36 months
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this specific time period allows us to determine the
prognostic value of the first initial PET/CT most rele-
vant to our patient population.
Due to the retrospective nature of this study, patients
with positive PET/CT and/or CA-125 received different
treatments, including additional surgical debulking,
chemotherapy, or conservative watchful waiting. There
has been conflicting data whether treatment of early re-
currence in asymptomatic patients (based on CA-125
and/or imaging) with traditional surgical debulking or
chemotherapy would lead to increased survival [23]. A
small retrospective study showed improved overall sur-
vival in asymptomatic patients whose disease was de-
tected by routine surveillance testing [24]. However,
two larger studies showed no survival benefit with early
treatment of relapsed based on raised CA-125 level
alone [25] or based on CA-125 levels and/or imaging
[26]. More recently, several clinical trials have shown
that bevacizumab, an angiotensin inhibitor, was able to
prolong progression-free survival in patients with ad-
vanced stage ovarian carcinoma [27–30]. Bevacizumab
has also been shown to increase overall survival in the
subset of patients with high risk of disease progression
[31]. With its high sensitivity in detection of disease re-
currence, posttreatment PET/CT may be able to iden-
tify this subset of patients with high risk of disease
progression who would benefit most from these newer
treatments.
In the current pilot study, a time window of 3 to
9 months was chosen as ovarian carcinoma patients at
our institution often returned for follow-up PET/CT
at this time interval. In future studies, the prognostic
value of posttreatment PET/CT and serum CA-125
can be determined at different time intervals to deter-
mine the ideal time window for posttreatment surveil-
lance. In future studies, it may be helpful to determine
if the quantitative analysis can refine prognostic value
of PET/CT.
Conclusions
Posttreatment PET/CT can predict survival of patients
with ovarian carcinoma. Addition of posttreatment PET/
CT to the CA-125 serum biomarker has an incremental
value in improving prognostic accuracy, particularly in
the subset of patients with negative CA-125.
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